{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:18:07Z","timestamp":1790763487624,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41417-018-0059-5","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T10:16:55Z","timestamp":1542017815000},"page":"334-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Intratumoral IFN-\u03b1 gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression"],"prefix":"10.1038","volume":"26","author":[{"given":"Aya","family":"Hirata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayoshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"59_CR1","first-page":"2489","volume":"58","author":"LM Pfeffer","year":"1998","unstructured":"Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Walter MR, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489\u201399.","journal-title":"Cancer Res"},{"key":"59_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","volume":"89","author":"M Ferrantini","year":"2007","unstructured":"Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89:884\u201393.","journal-title":"Biochimie"},{"key":"59_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/leu.2012.313","volume":"27","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia. 2013;27:803\u201312.","journal-title":"Leukemia"},{"key":"59_CR4","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.4049\/jimmunol.1290060","volume":"189","author":"AA Tarhini","year":"2012","unstructured":"Tarhini AA, Gogas H, Kirkwood JM. IFN-alpha in the treatment of melanoma. J Immunol. 2012;189:3789\u201393.","journal-title":"J Immunol"},{"key":"59_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.hoc.2011.04.010","volume":"25","author":"J Rosenblatt","year":"2011","unstructured":"Rosenblatt J, McDermott DF. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25:793\u2013812.","journal-title":"Hematol Oncol Clin North Am"},{"key":"59_CR6","doi-asserted-by":"publisher","first-page":"217ra3","DOI":"10.1126\/scitranslmed.3006353","volume":"6","author":"G Escobar","year":"2014","unstructured":"Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, Bondanza A, et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci Transl Med. 2014;6:217ra3.","journal-title":"Sci Transl Med"},{"key":"59_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/jgm.602","volume":"6","author":"K Hatanaka","year":"2004","unstructured":"Hatanaka K, Suzuki K, Miura Y, Yoshida K, Ohnami S, Kitade T, et al. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med. 2004;6:1139\u201348.","journal-title":"J Gene Med"},{"key":"59_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.bjc.6602713","volume":"93","author":"M Ohashi","year":"2005","unstructured":"Ohashi M, Yoshida K, Kushida M, Miura Y, Ohnami S, Ikarashi Y, et al. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br J Cancer. 2005;93:441\u20139.","journal-title":"Br J Cancer"},{"key":"59_CR9","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/j.1349-7006.2010.01578.x","volume":"101","author":"K Narumi","year":"2010","unstructured":"Narumi K, Kondoh A, Udagawa T, Hara H, Goto N, Ikarashi Y, et al. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Sci. 2010;101:1686\u201394.","journal-title":"Cancer Sci"},{"key":"59_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/gt.2011.73","volume":"19","author":"K Narumi","year":"2012","unstructured":"Narumi K, Udagawa T, Kondoh A, Kobayashi A, Hara H, Ikarashi Y, et al. In vivo delivery of interferon-alpha gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. Gene Ther. 2012;19:34\u201348.","journal-title":"Gene Ther"},{"key":"59_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00262-008-0616-0","volume":"58","author":"H Hara","year":"2009","unstructured":"Hara H, Kobayashi A, Narumi K, Kondoh A, Yoshida K, Nishimoto T, et al. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Immunother. 2009;58:1007\u201321.","journal-title":"Cancer Immunol Immunother"},{"key":"59_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1349-7006.2007.00408.x","volume":"98","author":"H Hara","year":"2007","unstructured":"Hara H, Kobayashi A, Yoshida K, Ohashi M, Ohnami S, Uchida E, et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci. 2007;98:455\u201363.","journal-title":"Cancer Sci"},{"key":"59_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cas.12332","volume":"105","author":"K Aida","year":"2014","unstructured":"Aida K, Miyakawa R, Suzuki K, Narumi K, Udagawa T, Yamamoto Y, et al. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-alpha gene therapy for pancreatic cancer. Cancer Sci. 2014;105:159\u201367.","journal-title":"Cancer Sci"},{"key":"59_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/cgt.2014.60","volume":"21","author":"H Hashimoto","year":"2014","unstructured":"Hashimoto H, Ueda R, Narumi K, Heike Y, Yoshida T, Aoki K. Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther. 2014;21:532\u201341.","journal-title":"Cancer Gene Ther"},{"key":"59_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1084\/jem.20070081","volume":"204","author":"BD Sather","year":"2007","unstructured":"Sather BD, Treuting P, Perdue N, Miazqowicz M, Fontenot JD, Rudensky AY, et al. Altering the distribution of Foxp3(\u2009+\u2009) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med. 2007;204:1335\u201347.","journal-title":"J Exp Med"},{"key":"59_CR16","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1084\/jem.20072594","volume":"205","author":"JC Dudda","year":"2008","unstructured":"Dudda JC, Perdue N, Bachtanian E, Campbell DJ. Foxp3\u2009+\u2009regulatory T cells maintain immune homeostasis in the skin. J Exp Med. 2008;205:1559\u201365.","journal-title":"J Exp Med"},{"key":"59_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4436","volume":"5","author":"H Fu","year":"2014","unstructured":"Fu H, Kishore M, Gittens B, Wang G, Coe D, Komarowska I, et al. Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation. Nat Commun. 2014;5:3436.","journal-title":"Nat Commun"},{"key":"59_CR18","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1158\/0008-5472.CAN-14-3499","volume":"75","author":"D Anz","year":"2015","unstructured":"Anz D, Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, et al. Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression. Cancer Res. 2015;75:4483\u201393.","journal-title":"Cancer Res"},{"key":"59_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/BF03402119","volume":"5","author":"K Aoki","year":"1999","unstructured":"Aoki K, Barker C, Danthinne X, Imperiale MJ, Nabel GJ. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol Med. 1999;5:224\u201331.","journal-title":"Mol Med"},{"key":"59_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/mthe.2001.0302","volume":"3","author":"M Nakano","year":"2001","unstructured":"Nakano M, Aoki K, Matsumoto N, Ohnami S, Hatanaka K, Hibi T, et al. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. Mol Ther. 2001;3:491\u20139.","journal-title":"Mol Ther"},{"key":"59_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","volume":"97","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006;97:1139\u201346.","journal-title":"Cancer Sci"},{"key":"59_CR22","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/ijc.23392","volume":"122","author":"Y Mizukami","year":"2008","unstructured":"Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3\u2009+\u2009regulatory T cells in gastric cancer. Int J Cancer. 2008;122:2286\u201393.","journal-title":"Int J Cancer"},{"key":"59_CR23","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.4049\/jimmunol.182.3.1746","volume":"182","author":"MC Tan","year":"2009","unstructured":"Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182:1746\u201355.","journal-title":"J Immunol"},{"key":"59_CR24","doi-asserted-by":"publisher","first-page":"14978","DOI":"10.1073\/pnas.0809784106","volume":"106","author":"C Porta","year":"2009","unstructured":"Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA. 2009;106:14978\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"59_CR25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.4049\/jimmunol.172.3.1407","volume":"172","author":"T Katakura","year":"2004","unstructured":"Katakura T, Miyazaki M, Kobayashi M, Herndon DN, Suzuki F. CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol. 2004;172:1407\u201313.","journal-title":"J Immunol"},{"key":"59_CR26","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1158\/0008-5472.CAN-12-3788","volume":"73","author":"N Bacher","year":"2013","unstructured":"Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res. 2013;73:5647\u201356.","journal-title":"Cancer Res"},{"key":"59_CR27","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.4049\/jimmunol.0900526","volume":"184","author":"L Pace","year":"2010","unstructured":"Pace L, Vitale S, Dettori B, Palombi C, La Sorsa V, Belardelli F, et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol. 2010;184:5969\u201379.","journal-title":"J Immunol"},{"key":"59_CR28","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/eji.200635972","volume":"36","author":"G Wirnsberger","year":"2006","unstructured":"Wirnsberger G, Hebenstreit D, Posselt G, Horejs-Hoeck J, Duschl A. IL-4 induces expression of TARC\/CCL17 via two STAT6 binding sites. Eur J Immunol. 2006;36:1882\u201391.","journal-title":"Eur J Immunol"},{"key":"59_CR29","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.humimm.2007.10.012","volume":"68","author":"E Maier","year":"2007","unstructured":"Maier E, Wirnsberger G, Horejs-Hoeck J, Duschl A, Hebenstreit D. Identification of a distal tandem STAT6 element within the CCL17 locus. Hum Immunol. 2007;68:986\u201392.","journal-title":"Hum Immunol"},{"key":"59_CR30","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.4049\/jimmunol.173.12.7565","volume":"173","author":"PC Fulkerson","year":"2004","unstructured":"Fulkerson PC, Zimmermann N, Hassman LM, Finkelman FD, Rothenberg ME. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma. J Immunol. 2004;173:7565\u201374.","journal-title":"J Immunol"},{"key":"59_CR31","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.4049\/jimmunol.163.7.3834","volume":"163","author":"S Gupta","year":"1999","unstructured":"Gupta S, Jiang M, Pernis AB. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J Immunol. 1999;163:3834\u201341.","journal-title":"J Immunol"},{"key":"59_CR32","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011;17:2619\u201327.","journal-title":"Clin Cancer Res"},{"key":"59_CR33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.0022-202X.2005.23840.x","volume":"125","author":"M Komine","year":"2005","unstructured":"Komine M, Kakinuma T, Kagami S, Hanakawa Y, Hashimoto K, Tamaki K. Mechanism of thymus- and activation-regulated chemokine (TARC)\/CCL17 production and its modulation by roxithromycin. J Invest Dermatol. 2005;125:491\u20138.","journal-title":"J Invest Dermatol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0059-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0059-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0059-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:16:00Z","timestamp":1694045760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-018-0059-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":33,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1038\/s41417-018-0059-5","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"3 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}